证券代码：301235 证券简称：华康洁净 公告编号：2025-114 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、华医转债（债券代码：123251）转股期限为 2025 年 6 月 27 日至 2030 年 12 月 22 日；最新有效的转股价格为人民币 22.43 元/股。 2、2025 年第三季度共有 486,482 张"华医转债"完成转股（票面金额共计 48,648,200 元人民币），共计转成 2,168,654 股"华康洁净"股票（证券代码： 301235）。 3、截至 2025 年第三季度末，公司剩余可转换公司债券张数为 7,013,428 张， 票面总金额为 701,342,800 元人民币。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》的有关规定，武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）现将 2025 年第三季度 ...

| 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-113 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 关于股东减持至5%以下暨权益变动的提示性公告 公司股东阳光人寿保险股份有限公司保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 一、本次权益变动的基本情况 （一）持股比例被动稀释 3、阳光人寿不属于公司控股股东、实际控制人及其一致行动人，本次权益变动不会导致公 司控股股东及实际控制人发生变化，不会对公司治理结构及持续经营产生重大影响。 经中国证券监督管理委员会《关于同意武汉华康世纪医疗股份有限公司向不特定对象发行可 转换公司债券注册的批复》(证监许可[2024]220号)同意注册，公司于2024年12月23日向不特定 对象发行可转换公司债券750万张，每张面值为100元，募集资金总额为人民币750,000,000.00元， 公司于2025年9月8日在巨潮资讯网披露了《关于持股5% ...

武汉华康世纪洁净科技股份有限公司 简式权益变动报告书 上市公司名称：武汉华康世纪洁净科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：华康洁净 股票代码：301235 信息披露义务人：阳光人寿保险股份有限公司 住所/注册地址：海南省三亚市迎宾路 360-1 号三亚阳光金融广场 16 层 股份变动性质：股份数量减少、持股比例被动稀释（股权比例下降至 5%以下） 签署日期：2025 年 9 月 29 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（简称"《证券法》"） 《上市公司收购管理办法》（简称"《收购办法》"）《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制 本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购办法》规定，本报告书已全面披露了信息披露义 务人在武汉华康世纪洁净科技股份有限公司（以下简称"华康洁净"或"公司"） 拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信息外， 信息披露义务人没有通过任何其他方式增加或减少其在华康洁净拥有权益的股 份。 四、本次权益变动 ...

Core Viewpoint - Huakang Clean achieved a significant increase in stock price and trading volume, indicating strong market interest and potential growth in the medical purification system sector [1][2]. Group 1: Financial Performance - For the first half of 2025, Huakang Clean reported revenue of 835 million yuan, representing a year-on-year growth of 50.73% [2]. - The net profit attributable to the parent company reached 18.68 million yuan, showing a substantial increase of 273.48% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 40.02 million yuan, with 29.46 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of September 19, the number of Huakang Clean's shareholders decreased by 2.96% to 10,000, while the average circulating shares per person increased by 3.05% to 7,272 shares [2]. - On September 25, Huakang Clean's financing buy-in amounted to 20.90 million yuan, with a net financing purchase of 1.18 million yuan, indicating strong investor interest [1]. - The total financing and securities balance reached 62.02 million yuan, accounting for 1.67% of the circulating market value, which is above the 90th percentile of the past year [1]. Group 3: Business Overview - Huakang Clean, established on November 12, 2008, specializes in the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1]. - The revenue composition of Huakang Clean includes 85.24% from purification system integration, 8.53% from medical consumables, 3.74% from medical equipment sales, and 1.88% from operation services [1]. Group 4: Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Anxin Medical Health Stock A, which is the fifth largest shareholder with 652,800 shares, and Nuoan Multi-Strategy Mixed A, the tenth largest shareholder with 429,900 shares, both being new entrants [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇9月25日丨华康洁净(301235.SZ)公布，公司于2025年8月28日在创业板信息披露网站巨潮资讯网 上披露了《关于项目预中标的提示性公告》。近日，公司收到招标人浙江滨海新区投资发展集团有限公 司发出的《中标通知书》，确认公司为"浙江省肿瘤医院绍兴院区(浙江滨海医院)新建工程医用净化专 项工程"项目的中标供应商。项目预计总金额为13,627.0305万元，占公司2024年度经审计营业收入的 7.98%，项目的履行不影响公司业务的独立性，如本项目签订正式合同并顺利实施，预计会对公司未来 年度的净利润产生积极的影响。 ...

本项目为综合三甲医院，总建筑面积约50万平方米，总投资约50亿。本标段为净化系统专项工程设施采 购及安装。公司中标内容范围包括施工图范围内的净化系统专项的相关内容，包括外科ICU、血液层流 病房、回旋加速医护净化、内科ICU、肠内营养区、淋巴血液病房、检验科、输血科、血透区、应急检 验科、急诊手术、综合ICU、产科、NICU、供应中心、手术部及手术部办公区等，具体详见招标文 件、设计图、工程量清单。中标价为1.36亿元。 智通财经APP讯，华康洁净(301235.SZ)公告，公司收到招标人浙江滨海新区投资发展集团有限公司发出 的《中标通知书》，确认公司为"浙江省肿瘤医院绍兴院区(浙江滨海医院)新建工程医用净化专项工 程"项目的中标供应商。 ...

Core Viewpoint - The company Huakang Clean (301235.SZ) has been awarded a contract for the medical purification special project at the Zhejiang Provincial Tumor Hospital Shaoxing Branch, confirming its role as the supplier for this significant construction project [1] Group 1: Project Details - The project involves the construction of a comprehensive tertiary hospital with a total building area of approximately 500,000 square meters and a total investment of around 5 billion [1] - The scope of the contract includes the procurement and installation of purification system facilities, covering various critical areas such as surgical ICUs, blood flow layer wards, and emergency testing departments [1] - The awarded contract value for the purification system special project is 136 million [1]

华康洁净公告，公司中标"浙江省肿瘤医院绍兴院区(浙江滨海医院)新建工程医用净化专项工程"项目， 中标金额为1.36亿元，占公司2024年度经审计营业收入的7.98%。该项目为综合三甲医院，总建筑面积 约50万平方米，总投资约50亿，公司负责净化系统专项工程设施采购及安装。项目的履行预计会对公司 未来年度的净利润产生积极的影响。 ...

转债代码：123251 转债简称：华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025-112 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日在创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于 项目预中标的提示性公告》（公告编号：2025-104）。近日，公司收到招标人浙 江滨海新区投资发展集团有限公司发出的《中标通知书》，确认公司为"浙江省 肿瘤医院绍兴院区(浙江滨海医院)新建工程医用净化专项工程"项目的中标供应 商。现将中标项目的主要内容公告如下： 7、工程质量：合格，配合总承包单位确保钱江杯，争创鲁班奖。 二、交易对手方情况 1、单位名称：浙江滨海新区投资发展集团有限公司 2、法定代表人：赵溢峰 一、中标项目基本情况 1、建设地点：绍兴滨海新区江滨区,海滨路以西,开元东路以南,海华路以东, 乾诚道以北。 2、 建设规模：本项目为综合三甲医院，总建筑面积约 5 ...

Core Viewpoints - The report highlights the strong growth potential of Huakang Clean (301235) in the cleanroom integration service sector, driven by its dual focus on medical and electronic markets [4][10][12] - The company has a robust order backlog, with medical and laboratory cleanroom orders increasing from 1.727 billion yuan in 2022 to 3.706 billion yuan in the first half of 2025, indicating sustained revenue growth [4][10][12] - The establishment of an electronic division in 2024 is expected to enhance the company's market presence in the electronic cleanroom sector, leveraging existing expertise and local resources [4][10][12] - The report projects significant revenue growth for the company, with expected revenues of 2.542 billion yuan, 3.547 billion yuan, and 4.598 billion yuan for 2025-2027, representing year-on-year growth rates of 49%, 40%, and 30% respectively [4][10][12] Summary by Sections Company Overview - Huakang Clean was established in 2008 and has 17 years of experience in the cleanroom integration service industry, recognized as a national high-tech enterprise [4][10][12] - The company offers a full industry chain capability, including design, construction, procurement, and after-sales service, covering medical, laboratory, and electronic cleanroom sectors across over 20 provinces and regions in China [4][10][12] Medical Business Growth - The medical cleanroom market is fragmented, and Huakang Clean has successfully expanded its business despite challenging macroeconomic conditions [4][10][12] - The company has accumulated technical experience in hospital projects, which has facilitated its entry into the laboratory cleanroom sector [4][10][12] Electronic Cleanroom Sector - The company plans to leverage its medical sector experience to enter the larger electronic cleanroom market, having already secured multiple projects with high-profile clients [4][10][12] - The strategy involves targeting high-tier clients and their supply chains to ensure a successful market entry [4][10][12] Financial Projections - The report forecasts net profits of 153 million yuan, 225 million yuan, and 332 million yuan for 2025-2027, with growth rates of 129%, 47%, and 47% respectively [4][10][12] - The estimated reasonable market value for the company is 5.1 billion yuan, indicating a potential upside of approximately 43% from its market value as of September 15, 2025 [4][10][12]